Treats partial- onset or primary generalized tonic-clonic seizures. ANDA 217248, held by Alkem Labs Ltd. Topiramate.
As of Nov 15, 2026, ANDA 217248 (Topiramate), held by Alkem Labs Ltd, was first approved by FDA on Jun 20, 2023, with 3 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules is indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2023 | Original application | Approved | None posted |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Oct 5, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 5, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 5, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 20, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters